Fresenius holds above its 200-day line, shares trade steadily on Xetra

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 15:33.

Fresenius (DE0005785604) starts Thursday trading as a DAX healthcare stock on Xetra, with investors watching its technical picture rather than fresh corporate headlines. The shares remain above their 200-day moving average, according to current German quote platforms.

The current Fresenius chart

On finanzen.net the Fresenius shares recently showed a real-time level around 39.7 euros, with a slight intraday decline of around 0.5 percent compared with the previous close, and bid-ask quotes clustered narrowly around that mark.Realtime data from finanzen.net The trading venue is Xetra, where the order book highlights active liquidity with several thousand shares on both bid and ask sides across the top levels.Order book overview on finanzen.net

Fresenius is listed in the DAX Performance-Index, giving it a central role in the German large-cap healthcare segment, alongside peers such as Fresenius Medical Care and other service-focused healthcare groups.Index and profile on finanzen100 The chart has recently held comfortably above the 200-day line, a level that chart-oriented investors often treat as a medium-term trend indicator.

Sector signals from Fresenius Medical Care

The broader Fresenius universe currently sees more volatility at Fresenius Medical Care, which focuses on dialysis services and products. Investing.com reports that Fresenius Medical Care shares recently dropped around 4.6 percent to trade near 40.2 euros after a regulatory proposal by the U.S. Centers for Medicare & Medicaid Services (CMS) on dialysis reimbursement.Investing.com sector report on Fresenius Medical Care

The CMS proposal includes only a 1.1 percent increase in the base rate for the end-stage renal disease bundle payment from 2027, roughly half of what many investors had anticipated according to the analysis.German-language coverage on Investing.com At the same time, CMS plans to bundle phosphate binders into the payment system, which could affect demand for Fresenius Medical Care’s phosphate binder drug Velphoro. Analyst sentiment for Fresenius Medical Care remains cautious, with UBS reaffirming a Sell rating and a price target of 32 euros earlier in June.

The business behind the Fresenius stock

Fresenius is a diversified healthcare group, with major operations in hospital management, generic and specialty pharmaceuticals, and medical technology. A representative business pillar is Helios, one of Europe’s largest private hospital operators, where Fresenius generates a substantial share of revenue by running acute care hospitals and specialist clinics across Germany and Spain.Fresenius group business overview In addition, Fresenius Kabi supplies infusion therapies, clinical nutrition products and intravenous generics, supporting both inpatient and outpatient treatment settings.

Where the Fresenius shares trade today

The Fresenius shares (DE0005785604) trade on Xetra, with recent data from finanzen.net showing a price region around 39.7 euros on 2026-06-25, 10:21, in euros.Realtime quote snapshot

Disclaimer: This text is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. All data are based on sources believed to be reliable but may be subject to change. Investors should conduct their own research and, if necessary, consult a professional adviser before making investment decisions.